Tuesday, June 30, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Prostate Cancer


Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director
University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Kara M Olivier, NP, APRN-BC
Massachusetts General Hospital Cancer Center
Claire and John Bertucci Center for
Genitourinary Cancers
Boston, Massachusetts

Victoria Sinibaldi, RN, MS, CS, CANP, BC
Adult and Geriatric Nurse Practitioner
Research Associate in Oncology and Urology
Faculty, School of Medicine
Johns Hopkins University
Affiliate Staff, Johns Hopkins Hospital
Baltimore, Maryland

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Importance of disease-free interval, PSA level, PSA doubling time and other factors in the decision to initiate androgen deprivation therapy (ADT) for patients with PSA-only relapse after definitive treatment; defining M0 castration-resistant prostate cancer (CRPC) in the clinical setting
  • FDA approvals for and clinical outcomes with the next-generation antiandrogens apalutamide, darolutamide and enzalutamide for nonmetastatic CRPC; patient selection and practical integration into clinical algorithms
  • Spectrum and frequency of toxicities, including CNS-related adverse events (eg, fatigue, seizure, falls) associated with apalutamide, darolutamide and enzalutamide
  • Clinical, biologic and practical factors (eg, age, duration of therapy, extent and sites of metastases) guiding the choice between secondary hormonal therapy and chemotherapy for metastatic hormone-sensitive PC (mHSPC)
  • Role of enzalutamide or apalutamide in combination with ADT compared to ADT alone for patients with mHSPC
  • Key efficacy and safety outcomes from the Phase III ENZAMET study of enzalutamide with ADT versus other nonsteroidal antiandrogens with ADT as first-line therapy for mHSPC
  • Current and potential role of docetaxel with ADT and secondary hormonal therapy for mHSPC
  • Clinical and biologic factors affecting the sequence and selection of secondary hormonal therapy and cytotoxic therapy for patients with metastatic CRPC
  • Efficacy and safety of cabazitaxel versus alternative androgen receptor (AR)-targeted therapy (abiraterone or enzalutamide) for patients with metastatic CRPC who had received docetaxel and experienced disease progression on a prior AR-targeted agent; implications for therapeutic sequencing
  • Current role of AR splice variant 7 as a biomarker to predict resistance to secondary hormonal therapy and in clinical decision-making

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data in the therapeutic and supportive care of patients with early and advanced prostate cancer (PC).
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC, and apply this information in the discussion of nonresearch treatment options with patients.
  • Counsel patients with hormone-sensitive metastatic PC regarding the use of cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
  • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic castration-resistant PC.
  • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced PC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with PC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

A maximum of 1.5 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Participation Completion Requirements
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/ProstateCancer/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by USF Health, Research To Practice (RTP) or the ANCC. Any off-label use as declared by the FDA will be identified.

Disclosure Policy
USF Health adheres to ACCME and ANCC standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

FACULTYMs Olivier and Ms Sinibaldi have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr DreicerAdvisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelexis Inc, Pfizer Inc, Seattle Genetics. Dr SmithAdvisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Lilly.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

USF Health — USF Health CPD staff have no relevant conflicts of interest to disclose.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Equal Opportunity Statement
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Contact Information
If you have questions regarding credit, please contact cpdsupport@usf.edu, or call 813-224-7860.

This activity is supported by educational grants from Astellas and Pfizer, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.